Amal Melhem‐Bertrandt

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

Jonathan E. Rosenberg, Peter H. O’Donnell, Arjun Vasant Balar et al. · Journal of Clinical Oncology · 2019 · 626 citations · Full text

Medicine, Oncology, Pharmacology +17

Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast Cancer

Amal Melhem‐Bertrandt, Mariana Chávez‐MacGregor, Xiudong Lei et al. · Journal of Clinical Oncology · 2011 · 457 citations · Full text

Medicine, Oncology, Pharmacology +14

EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

Jonathan E. Rosenberg, Srikala S. Sridhar, Jingsong Zhang et al. · Journal of Clinical Oncology · 2020 · 327 citations · Full text

Medicine, Oncology, Pharmacology +17

Early onset HER2‐positive breast cancer is associated with germline <i>TP53</i> mutations

Amal Melhem‐Bertrandt, Jasmina Bojadzieva, Kaylene Ready et al. · Cancer · 2011 · 138 citations

Medicine, Oncology, Pathology +15

Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe

Johann S. de Bono, Simon Chowdhury, Susan Feyerabend et al. · European Urology · 2017 · 117 citations · Full text

Pharmacy, Oncology, Pharmacology +17